# Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

> **NCT02682511** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cumberland Pharmaceuticals** · enrollment: 34 (estimated)

## Conditions studied

- Scleroderma, Diffuse
- Scleroderma, Systemic
- Scleroderma, Limited
- Sclerosis, Progressive Systemic
- Skin Diseases
- Connective Tissue Diseases
- Pathologic Processes
- Autoimmune Diseases

## Interventions

- **DRUG:** Oral Ifetroban
- **DRUG:** Oral Placebo

## Key facts

- **NCT ID:** NCT02682511
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-01
- **Primary completion:** 2026-06
- **Final completion:** 2026-08
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02682511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02682511, "Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02682511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*